Masahito Tsurusawa, Masahiko Gosho, Tetsuya Mori, Tetsuo Mitsui, Shosuke Sunami, Ryoji Kobayashi, Reiji Fukano, Fumiko Tanaka, Naoto Fujita, Hiroko Inada, Katsuyoshi Koh, Tetsuya Takimoto, Akiko Saito, Junichiro Fujimoto, Atsuko Nakazawa, Keizo Horibe
BACKGROUND: Plasma monitoring of Methotrexate (MTX) levels is a standard approach to predict MTX-related toxicities in a high-dose (HD) MTX monotherapy for childhood acute lymphoblastic leukemia. However, it is uncertain whether plasma MTX levels can predict MTX-related toxicity in the HDMTX plus additional chemotherapy for childhood B-cell nonHodgkin lymphoma (B-NHL). PROCEDURES: To statistically analyze the relationship between MTX pharmacokinetic parameters and MTX-related toxicities, we collected data from patients with delayed MTX elimination (≥1 µM at 48 hr and/or ≥0...
February 2015: Pediatric Blood & Cancer